[Immunosuppressive medication in multiple sclerosis].

J A García Merino

PubMed · 12497298

[Immunosuppressive medication in multiple sclerosis].

Abstract

Immunosuppressive drugs have been used for decades in the treatment of multiple sclerosis. The recent availability of immunomodulators has caused a major change in the treatment of this disease, but has not meant the disappearance of the use of immunosuppressive drugs, some of which (such as mitoxantrone) have been introduced recently. At present, it is difficult to assess the precise indications for these drugs, since most efficacy studies were made before the availability of magnetic resonance imaging, on criteria which are now considered obsolete. Independently of their value in monotherapy, immunosuppressants may probably be useful in combination with immunomodulators. We review the experience with the most widely used immunosuppressants and mention those drugs which might be used in the near future.

Explore related subjects

Antimetabolites Antineoplastic Agents Azathioprine Cladribine Cyclophosphamide Cyclosporine Drug Therapy, Combination Humans Immunosuppressive Agents Methotrexate Mitoxantrone Multiple Sclerosis English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J A García Merino. [Immunosuppressive medication in multiple sclerosis].. https://pubmed.ncbi.nlm.nih.gov/12497298/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Biocompatibility of different barrier membranes in cultures of human CRL 11372 osteoblast-like cells: an immunohistochemical study.

OBJECTIVE: The aim of this study was to evaluate the biocompatibility of two different barrier materials in cultures of human osteoblast-like cells (CRL 11372) in vitro. MATERIAL AND METHODS: Polylactic acid (Epi-Guide; EG) and collagen membrane (Bio-Collagen, BC) were examined. To analyze the effect of materials on cell proliferation, cell numbers and cell viability, cells were cultured on the barrier membranes for 24 and 72 h. Cells plated on culture dishes (CD) served as positive controls. Cell proliferation rate was assessed by the bromodeoxyuridine (BrdU) immunohistochemical technique. The cell numbers of each well were counted. Cell viability was estimated by counting the number of cells, which excluded trypan blue solution. Scanning electron microscopy (SEM) was used to observe the interactions between osteoblastic cells and barrier membranes. RESULTS: The highest number of BrdU-labeled cells were seen on CD after both of the time periods. In comparison with the other two groups, BC showed significantly fewer cells after both time periods. Regarding cell numbers, after 24 and 72 h of incubations CD showed the highest number of cells. The number of viable cells was similar for all the groups. After 72 h for the EG group, SEM view showed flat cells. After 72-h time periods, the BC group revealed a weak adhesion of cells to the barriers. CONCLUSION: The results demonstrate that cells were able to proliferate on these materials and EG promoted the proliferation of human osteoblast like cells. We prefer to use the EG membrane.

Antimetabolites↗

PubMed2006

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

Antimetabolites↗

PubMed2006

Synthesis of a technetium-99m labeled tricyclic ganciclovir analog for non-invasive reporter gene expression imaging.

A potential radiopharmaceutical and HSV1-TK substrate, 3-((1,3-dihydroxypropan-2-yloxy)-methyl)-6-(4-(3-((2-mercaptoethyl)(2-(2-mercaptoethyl-amino)-ethyl)amino)propoxy)phenyl)-3H-imidazopurin-9(5H)-one-oxo-technetium(V), was synthesized via a converging approach and its chemical structure was comparatively characterized with a non-radioactive analog. The final radiochemical purity and yield were 97 and 73%, respectively.

Antimetabolites↗